直接面向消费者的测试(DTC):注定要连接或中断。买家要注意(传染病视角)

Q3 Medicine
Teofilo Borunda Duque Pharm.D., M.S. , Monique Dodd Pharm.D., Ph.C., MLS(ASCP)CM , Ramisha Ali Pharm.D. , Richard VanNess M.S. , David G. Grenache Ph.D., D(ABCC)
{"title":"直接面向消费者的测试(DTC):注定要连接或中断。买家要注意(传染病视角)","authors":"Teofilo Borunda Duque Pharm.D., M.S. ,&nbsp;Monique Dodd Pharm.D., Ph.C., MLS(ASCP)CM ,&nbsp;Ramisha Ali Pharm.D. ,&nbsp;Richard VanNess M.S. ,&nbsp;David G. Grenache Ph.D., D(ABCC)","doi":"10.1016/j.clinmicnews.2022.02.001","DOIUrl":null,"url":null,"abstract":"<div><p>Direct-to-consumer (DTC) testing continues to be a subject of debate throughout the medical community. DTC testing may be viewed as expanding access to health care<span><span>. Additionally, caution is needed in defining the role of DTC testing in the overall health care<span> continuum of the consumer, particularly with limited provider resources. The recent COVID-19 pandemic resulted in a shift of consumer health care expectations and triggered providers to restructure their </span></span>health care delivery services to create a more consolidated care model. There are several benefits from DTC testing that can help address this new restructure of health care, such as easy access to an available product and decreased person-to-person contact. However, there have been controversies regarding ethical considerations, appropriate specimen sampling, and evidence-based practices. This article provides an overview of DTC testing, advantages and concerns, considerations around infectious disease, and the potential role of the clinical laboratory to ensure safe and effective DTC testing services.</span></p></div>","PeriodicalId":39211,"journal":{"name":"Clinical Microbiology Newsletter","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Direct-to-Consumer Testing (DTC): Destined to Connect or Disrupt. Buyer Be Aware (An Infectious Disease Perspective)\",\"authors\":\"Teofilo Borunda Duque Pharm.D., M.S. ,&nbsp;Monique Dodd Pharm.D., Ph.C., MLS(ASCP)CM ,&nbsp;Ramisha Ali Pharm.D. ,&nbsp;Richard VanNess M.S. ,&nbsp;David G. Grenache Ph.D., D(ABCC)\",\"doi\":\"10.1016/j.clinmicnews.2022.02.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Direct-to-consumer (DTC) testing continues to be a subject of debate throughout the medical community. DTC testing may be viewed as expanding access to health care<span><span>. Additionally, caution is needed in defining the role of DTC testing in the overall health care<span> continuum of the consumer, particularly with limited provider resources. The recent COVID-19 pandemic resulted in a shift of consumer health care expectations and triggered providers to restructure their </span></span>health care delivery services to create a more consolidated care model. There are several benefits from DTC testing that can help address this new restructure of health care, such as easy access to an available product and decreased person-to-person contact. However, there have been controversies regarding ethical considerations, appropriate specimen sampling, and evidence-based practices. This article provides an overview of DTC testing, advantages and concerns, considerations around infectious disease, and the potential role of the clinical laboratory to ensure safe and effective DTC testing services.</span></p></div>\",\"PeriodicalId\":39211,\"journal\":{\"name\":\"Clinical Microbiology Newsletter\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-02-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Microbiology Newsletter\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0196439922000095\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Microbiology Newsletter","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0196439922000095","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2

摘要

直接面向消费者(DTC)的检测一直是医学界争论的主题。DTC检测可被视为扩大了获得卫生保健的机会。此外,在确定DTC检测在消费者整体保健连续体中的作用时需要谨慎,特别是在提供者资源有限的情况下。最近的COVID-19大流行导致消费者医疗保健期望的转变,并促使提供者重组其医疗保健服务,以创建更统一的医疗模式。DTC测试有几个好处,可以帮助解决这种新的医疗保健结构调整问题,例如更容易获得可用的产品和减少人与人之间的接触。然而,在伦理考虑、适当的标本取样和循证实践方面存在争议。本文概述了DTC检测、优点和关注的问题、围绕传染病的注意事项以及临床实验室在确保安全有效的DTC检测服务中的潜在作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Direct-to-Consumer Testing (DTC): Destined to Connect or Disrupt. Buyer Be Aware (An Infectious Disease Perspective)

Direct-to-consumer (DTC) testing continues to be a subject of debate throughout the medical community. DTC testing may be viewed as expanding access to health care. Additionally, caution is needed in defining the role of DTC testing in the overall health care continuum of the consumer, particularly with limited provider resources. The recent COVID-19 pandemic resulted in a shift of consumer health care expectations and triggered providers to restructure their health care delivery services to create a more consolidated care model. There are several benefits from DTC testing that can help address this new restructure of health care, such as easy access to an available product and decreased person-to-person contact. However, there have been controversies regarding ethical considerations, appropriate specimen sampling, and evidence-based practices. This article provides an overview of DTC testing, advantages and concerns, considerations around infectious disease, and the potential role of the clinical laboratory to ensure safe and effective DTC testing services.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical Microbiology Newsletter
Clinical Microbiology Newsletter Medicine-Infectious Diseases
CiteScore
2.20
自引率
0.00%
发文量
35
审稿时长
53 days
期刊介绍: Highly respected for its ability to keep pace with advances in this fast moving field, Clinical Microbiology Newsletter has quickly become a “benchmark” for anyone in the lab. Twice a month the newsletter reports on changes that affect your work, ranging from articles on new diagnostic techniques, to surveys of how readers handle blood cultures, to editorials questioning common procedures and suggesting new ones.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信